ReviewNature reviews. Nephrology2015
Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus.
Review in Nature reviews. Nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 324 citations in OpenAlex.
- Effects of salt and protein intake on polyuria in V2RA-treated ADPKD patients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Trial
- Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.Clinical journal of the American Society of Nephrology : CJASN · 2022Trial
- Effects of sildenafil, metformin, and simvastatin on ADH-independent urine concentration in healthy volunteers.Physiological reports · 2018Trial
- Tonicity drives collecting duct maturation in the mammalian kidney.Nature communications · 2026Article
- Article
- X-Linked Nephrogenic Diabetes Insipidus Associated with the AVPR2 c.964C>T (p.Pro322Ser) Variant: A Family Case Series.Journal of clinical medicine · 2026Article
- Transcriptional regulatory factors of the Aqp2 gene.Kidney research and clinical practice · 2026Article
- Article
- Article
- De novo GNAS-Gsα variant (p.Thr55Ala) with constitutive gain-of-function effects on AVPR2 and PTH1R signalings.Journal of human genetics · 2026Article
- Arginine vasopressin disorders, formerly known as diabetes insipidus.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Copeptin in the diagnosis and management of renal tubular disorders.Pediatric nephrology (Berlin, Germany) · 2026Review
- Identification of a novel large deletion mutation in theTranslational pediatrics · 2026Article
- Arginine Vasopressin Deficiency and Oxytocin Deficiency in the Endocrine Clinic.The Journal of clinical endocrinology and metabolism · 2026Review
- [Analysis of stimulating factors for serum copeptin based on liquid chromatography-tandem mass spectrometry].Se pu = Chinese journal of chromatography · 2026Article
- CANDID Study: Clinical and Molecular Characterization of Congenital Arginine Vasopressin-Resistance and the Use of a Novel Diagnostic Biomarker in Indian Children.Indian journal of pediatrics · 2026Article
- Sodium and Water Homeostasis in Children: Pathogenesis, Diagnosis, and Treatment.Journal of clinical medicine · 2026Review
- Reversible Nephrogenic Diabetes Insipidus Induced by Lithium: A Case Report.Case reports in nephrology · 2026Article
- Infant Nephrogenic Diabetes Insipidus: Challenges Leading to Delayed Management.Case reports in medicine · 2026Article
- CREB-Family Transcription Factors and Vasopressin-Mediated Regulation of Aqp2 Gene Transcription.Journal of the American Society of Nephrology : JASN · 2026Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Healthy kidneys maintain fluid and electrolyte homoeostasis by adjusting urine volume and composition according to physiological needs. The final urine composition is determined in the last tubular segment: the collecting duct. Water permeability in the collecting duct is regulated by arginine vasopressin (AVP). Secretion of AVP from the neurohypophysis is regulated by a complex signalling network that involves osmosensors, barosensors and volume sensors. AVP facilitates aquaporin (AQP)-mediated water reabsorption via activation of the vasopressin V2 receptor (AVPR2) in the collecting duct, thus enabling concentration of urine. In nephrogenic diabetes insipidus (NDI), inability of the kidneys to respond to AVP results in functional AQP deficiency. Consequently, affected patients have constant diuresis, resulting in large volumes of dilute urine. Primary forms of NDI result from mutations in the genes that encode the key proteins AVPR2 and AQP2, whereas secondary forms are associated with biochemical abnormalities, obstructive uropathy or the use of certain medications, particularly lithium. Treatment of the disease is informed by identification of the underlying cause. Here we review the clinical aspects and diagnosis of NDI, the various aetiologies, current treatment options and potential future developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.